Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial

Impact of ultra‐thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial

“…9 In these settings, all DES features (ranging from strut thickness and composition to the polymer and drug eluted) are involved in the procedural and clinical success, as already demonstrated in the past for regular percutaneous coronary intervention (PCI). [10][11][12][13] In the PRISON IV randomized multicentre trial, successfully reanalysed CTO lesions were randomly allocated in a 1:1 fashion to stent implantation with Orsiro, a hybrid ultrathin-strut sirolimus-eluting stent (SES, Biotronik, Berlin, Germany) or Xience, a thin-strut (81 μm) everolimus-eluting stents (EES, Abbott Vascular, Santa Clara, CA). 14 The SES study device did not meet the primary non-inferiority endpoint of in-segment late lumen loss (LLL) estimated by Quantitative Coronary Analysis (QCA) at 8 month of angiographic follow-up, mainly because of an increased rate of focal instent restenosis in the SES group.…”

Effect on Clinical Restenosis of an Ultra‐Thin‐Strut Bare Metal Cobalt‐Chromium Stent Versus a Thin‐Strut Stainless Steel Stent

“…5,6,10 The demonstration of the effect of the strut thickness on stent restenosis derives from several randomized trials in which stents made of the same material but with different strut thickness and different design have been compared. 5,6 A thin-strut design significantly reduced late lumen loss and consequently the risk of angiographic and clinical restenosis when compared with thick (>0.1 mm) strut stainless steel stents. The use of cobalt-chromium coating which reduces the strut thickness brought to a reduction of TLR.…”

“…Improved design of BMS and reduced strut thickness result in better outcomes. [4][5][6][7][8][9][10] Thinner strut cobalt-chromium (Cro-Co) BMS has advantages over stainless steel (SS) BMS in terms of significant reduction of neointimal formation, increased flexibility, and better deliverability without compromising radial strength or radio-opacity. This has resulted in a significant reduction of neointimal formation and subsequent target-lesion revascularization (TLR) compared with SS BMS.…”

TCT-185 Three-Year Safety And Efficacy Of Newer Generation Limus-Eluting Stents Compared To Bare Metal Stents and First-Generation Sirolimus-eluting Stents In Patients With Acute Coronary Syndrome

“…Cobalt-chromium alloys in the 2nd-generation drug-eluting stents are thinner (80-90 mm) than the stainless steel Cypher (140 mm). Thinner stent struts have been reported to show a reduction in clinical restenosis, likely as a result of less stent-induced injury and inflammation [21].…”